BioHarvest Sciences (BHST) Stock Price, News & Analysis

Company Overview

BioHarvest Sciences Inc. is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets. Utilizing its “living plant cell” methodology, BioHarvest Sciences creates concentrates rich in natural antioxidants, peptides and other bioactive molecules. These ingredients are formulated for skin-care serums, dietary supplements and functional beverages, targeting consumers and manufacturers seeking clean-label and scientifically backed botanical solutions.

BioHarvest Sciences has pursued collaborative partnerships with research institutions and commercial enterprises to advance its cell-culture platform and expand market reach. While its technology development is headquartered in North America, the company’s ingredients have attracted interest from cosmetics and food firms in Europe and Asia. As it continues to scale production and refine its bioreactor processes, BioHarvest Sciences positions itself at the intersection of cellular agriculture and plant-derived therapeutics.

Key Stats

• Today's Range: $8.70 to $9.30
• 50-Day Range: $6.84 to $9.60
• 52-Week Range: $4.66 to $9.90
• Volume: 9,702 shs
• Average Volume: 25,200 shs
• Market Capitalization: $147.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.67
• Consensus Rating: Buy

BHST Stock Analysis - Frequently Asked Questions

How have BHST shares performed this year?

BioHarvest Sciences' stock was trading at $6.18 at the beginning of the year. Since then, BHST shares have increased by 45.0% and is now trading at $8.96.

How were BioHarvest Sciences' earnings last quarter?

BioHarvest Sciences Inc. (NASDAQ:BHST) announced its quarterly earnings results on Monday, August, 11th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.04. The firm earned $8.52 million during the quarter, compared to analysts' expectations of $8.53 million. BioHarvest Sciences had a negative net margin of 39.95% and a negative trailing twelve-month return on equity of 11,357.84%.
Read the conference call transcript.

Who are BioHarvest Sciences' major shareholders?

BioHarvest Sciences' top institutional investors include Magnus Financial Group LLC (0.43%) and True North Advisors LLC (0.13%).

How do I buy shares of BioHarvest Sciences?

Shares of BHST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/11/2025
• Today: 9/19/2025
• Next Earnings (Estimated): 11/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BHST
• Previous Symbol: NASDAQ:BHST
• CIK: 1723464
• Web: bioharvest.com
• Phone: 646-863-2177
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioHarvest Sciences: $13.67
• High Price Target: $15.00
• Low Price Target: $12.00
• Potential Upside/Downside: +52.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$12.91 million
• Net Margins: -39.95%
• Pretax Margin: -39.67%
• Return on Equity: -11,357.84%
• Return on Assets: -39.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.60
• Quick Ratio: 0.36

Sales & Book Value

• Annual Sales: $25.19 million
• Price / Sales: 5.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 112.00

Miscellaneous

• Outstanding Shares: 16,420,000
• Free Float: N/A
• Market Cap: $147.12 million
• Optionable: N/A
• Beta: 0.68